10-Q: Clarivate Q1 2026: Revenue Dip, Profitability Improves

Clarivate Plc reported a slight revenue decrease in Q1 2026 compared to the prior year, but saw an improvement in operating income and Adjusted EBITDA margin.

Summary

• Clarivate Plc's Q1 2026 revenues were $585.5 million, a decrease from $593.7 million in Q1 2025.
• Operating income improved to $30.2 million in Q1 2026 from a loss of $20.8 million in Q1 2025.
• Net loss for the quarter was $40.2 million, an improvement from a net loss of $103.9 million in the prior year period.
• Adjusted EBITDA increased to $241.2 million from $233.2 million in Q1 2025, with the Adjusted EBITDA margin rising to 41.2% from 39.3%.
• The company repurchased approximately 7.0 million ordinary shares for $18.1 million during the quarter.
• Restructuring costs decreased significantly to $12.0 million from $24.7 million in the prior year period, largely due to the ongoing Value Creation Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with improved profitability and cost management offsetting a slight revenue decline, but with ongoing strategic uncertainties regarding the LS&H divestiture.

Positives

• Operating income turned positive, reaching $30.2 million in Q1 2026, a significant improvement from a loss of $20.8 million in Q1 2025.
• Adjusted EBITDA increased by 3.4% to $241.2 million, and the Adjusted EBITDA margin improved to 41.2% from 39.3% in the prior year.
• Net loss narrowed substantially to $40.2 million from $103.9 million in the comparable period.
• Subscription revenues saw an increase of 2.3% to $397.5 million, driven by organic growth from new sales and pricing.
• Re-occurring revenues also increased by 2.5% to $108.6 million, primarily due to foreign currency movements.
• The company continues to manage its debt, with total debt outstanding decreasing to $4,326.8 million from $4,469.9 million.
• Share repurchases demonstrate a commitment to returning value to shareholders, with $18.1 million spent in Q1 2026.

Negatives

• Total revenues decreased by 1.4% to $585.5 million in Q1 2026 compared to $593.7 million in Q1 2025.
• Transactional revenues experienced a significant decline of 20.0% to $79.4 million, largely due to product group wind-downs.
• Academia & Government (A&G) segment revenues decreased by 2.5% to $295.0 million, impacted by product group wind-downs.
• Life Sciences & Healthcare (LS&H) segment revenues decreased by 5.1% to $93.3 million, also due to product group wind-downs.
• Net cash provided by operating activities decreased by 21% to $134.7 million from $171.2 million in the prior year.
• Free cash flow decreased by 28% to $78.9 million from $110.3 million in the prior year.

Risks

• The company is pursuing a sale of its Life Sciences & Healthcare segment, and there is no assurance that this sale process will result in a transaction.
• The company faces ongoing legal proceedings, including consolidated securities class action complaints, with outcomes and potential financial impact being uncertain.
• Dependence on third parties for data, information, and services poses a risk.
• Increased access to free or inexpensive information sources could impact the business model.
• The highly competitive industry in which Clarivate operates presents a risk to its market position and revenue.
• Maintaining high annual renewal rates is crucial and could be impacted by product acceptance and technological changes.
• Reductions in customer research budgets or government funding could negatively affect revenues.
• The success of the Value Creation Plan is critical for future performance.
• Loss of or inability to attract and retain key personnel is a significant risk.
• Exposure to risks from international operations, including potential adverse tax consequences and currency fluctuations.
• Cybersecurity risks, including disruptions and breaches of computer systems, are a concern.
• Compliance with data privacy and cybersecurity laws is essential and carries inherent risks.

Future Outlook

The company is pursuing a sale of its Life Sciences & Healthcare segment, which it believes will allow for increased focus on its Academia & Government and Intellectual Property businesses and strengthen its balance sheet through reduced leverage. Proceeds from a potential sale are anticipated to reduce leverage. The company is in active discussions with interested parties but cannot assure a transaction will occur. The Value Creation Plan is expected to continue throughout 2026.

Management Comments

• We believe that a potential sale [of LS&H] will allow us to increase our focus on our A&G and IP businesses, and we anticipate that proceeds from a potential sale would strengthen our balance sheet through reduced leverage.
• Our aim is to fuel the worlds greatest breakthroughs by harnessing the power of human ingenuity.
• We are committed to driving innovation and delivering value to our customers across the entire innovation lifecycle.

Industry Context

StockSavvy.ai notes that Clarivate's Q1 2026 results reflect ongoing industry trends of strategic portfolio review and optimization, particularly in the information services sector. The reported revenue decline, while concerning, is partially offset by improvements in profitability metrics like Adjusted EBITDA margin, suggesting effective cost management and a focus on higher-margin segments. The pursuit of divesting the Life Sciences & Healthcare segment aligns with a broader industry movement towards specialization and deleveraging to enhance shareholder value.

Comparison to Industry Standards

• Clarivate's Adjusted EBITDA margin of 41.2% in Q1 2026 is generally considered strong within the information services and data analytics industry, often outperforming broader software and IT services companies.
• Competitors like RELX (formerly Reed Elsevier) and Informa also operate in similar data and analytics spaces, with RELX often reporting EBITDA margins in the mid-to-high 20s and Informa in the low 20s, though direct comparison is complex due to differing business models and segment compositions.
• The reported organic revenue growth of 2.2% for the company is modest and aligns with the mature growth rates seen in many established data and analytics providers, contrasting with higher growth rates in emerging technology sectors.
• The annual renewal rate of 92.5% is a positive indicator and is generally considered a benchmark for high customer retention in subscription-based businesses, comparable to leading SaaS companies.

Legal Proceedings

• Three putative securities class action complaints were filed in the U.S. District Court for the Eastern District of New York against Clarivate and certain executives/directors, alleging weaknesses in internal controls and financial reporting. These have been consolidated and amended, with defendants' motions to dismiss granted in part and denied in part in March 2026.
• A related class action in Pennsylvania state court asserts claims under the Securities Act of 1933 based on similar allegations regarding offering documents for share issuances in June and September 2021. This case has seen preliminary objections sustained in part, with a third amended complaint filed in March 2026 and preliminary objections filed by the company in April 2026.

Stakeholder Impact

• Shareholders: The ongoing share repurchase program may provide some support to share price. The potential divestiture of LS&H and the outcome of legal proceedings introduce uncertainty.
• Employees: Restructuring costs indicate potential workforce reductions as part of the Value Creation Plan and Segment Optimization programs.
• Creditors: The company's stated intention to strengthen its balance sheet through reduced leverage may be viewed positively by creditors.
• Customers: Continued focus on subscription revenues and renewal rates suggests an effort to maintain customer relationships, though product group wind-downs could impact some offerings.

Next Steps

• Continue pursuing the sale of the Life Sciences & Healthcare segment.
• Focus on Academia & Government and Intellectual Property businesses.
• Strengthen the balance sheet through reduced leverage, potentially from proceeds of the LS&H sale.
• Continue the Value Creation Plan throughout 2026.
• Monitor and manage ongoing legal proceedings.

Key Dates

Recommendation

The company shows signs of operational improvement with increased profitability and a strong Adjusted EBITDA margin, alongside a stable renewal rate. However, the slight revenue decline, ongoing legal proceedings, and the uncertainty surrounding the potential divestiture of a significant segment (LS&H) warrant a cautious approach. A 'hold' recommendation reflects the balance between these positive operational developments and the existing strategic and legal uncertainties.

Keywords

Clarivate, SEC Filing, 10-Q, Financial Results, Q1 2026, Revenue, Adjusted EBITDA, Restructuring, Share Repurchase, Intellectual Property, Academia, Government, Life Sciences, Healthcare